NCT05170256

Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

HERES Trial: Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Morten Mau-Sørensen · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The study aims to determine the efficacy of trastuzumab added to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab) in patients with HER2 positive Esophageal squamous cell carcinoma (ESCC) determined by 6 months progression free survival (PFS) (RECIST 1.1).

Conditions

• Esophageal Squamous Cell Carcinoma
• HER-2 Protein Overexpression
• HER-2 Gene Amplification

Interventions

Type	Name	Description
DRUG	Trastuzumab	Addition of trastuzumab to standard treatment (fluoropyrimidine/platinum doublet with pembrolizumab)

Timeline

• Start date: 2022-02-04
• Primary completion: 2025-01-01
• Completion: 2025-01-01
• First posted: 2021-12-27
• Last updated: 2022-08-12

Locations

2 sites across 1 country: Denmark